Tomas Lorant News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Tomas Lorant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Tomas Lorant Today - Breaking & Trending Today

Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study

Published: October 17, 2023

/PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced results...

Source: prnewswire.com

Related Topics:

United StatesUppsala LanLos AngelesStanley JordanHansa BiopharmaStephanie KenneyTomas LorantPrnewswire Hansa BiopharmaKlaus SindahlSinai Medical CenterUppsala University HospitalHmedides Clinical Trial ProgramEuropean UnionEuropean Medicines AgencyAmerican Kidney FundVp Global Corporate AffairsNasdaq StockholmAmerican JournalAssociate ProfessorTransplant SurgeryTransplant ImmunologyCedars Sinai Medical CenterHuman Leukocyte AntigensPriority MedicinesIdes Clinical Trial

Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data

Published: October 17, 2023

LUND, Sweden, Oct. 17, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in...

Source: notimerica.com

Related Topics:

Uppsala LanUnited StatesHansa Biopharmahansa BiopharmaTomas LorantLos AngelesHansa BiopharmaPrnewswire Hansa BiopharmaStanley JordanKlaus SindahlStephanie KenneyHmedides Clinical Trial ProgramUppsala University HospitalSinai Medical CenterAmerican Kidney FundEuropean UnionEuropean Medicines AgencyNasdaq StockholmAmerican JournalAssociate ProfessorTransplant SurgeryTransplant ImmunologyCedars Sinai Medical CenterHuman Leukocyte AntigensInvestor RelationsmCorporate Affairsm